-$0.96 EPS Expected for Achaogen (AKAO) This Quarter

Brokerages expect Achaogen (NASDAQ:AKAO) to announce earnings of ($0.96) per share for the current quarter, according to Zacks. Five analysts have provided estimates for Achaogen’s earnings, with the lowest EPS estimate coming in at ($1.10) and the highest estimate coming in at ($0.83). Achaogen reported earnings of ($0.78) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 23.1%. The company is scheduled to announce its next quarterly earnings results on Thursday, August 2nd.

According to Zacks, analysts expect that Achaogen will report full year earnings of ($3.22) per share for the current year, with EPS estimates ranging from ($3.53) to ($2.96). For the next fiscal year, analysts expect that the firm will post earnings of ($2.41) per share, with EPS estimates ranging from ($3.28) to ($1.59). Zacks’ EPS calculations are an average based on a survey of research analysts that cover Achaogen.

Achaogen (NASDAQ:AKAO) last issued its quarterly earnings data on Friday, May 4th. The biopharmaceutical company reported ($1.06) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.89) by ($0.17). Achaogen had a negative return on equity of 90.07% and a negative net margin of 2,384.08%. The business had revenue of $2.14 million for the quarter, compared to analysts’ expectations of $1.25 million.

AKAO has been the subject of several recent analyst reports. Needham & Company LLC reissued a “buy” rating and set a $20.00 price objective on shares of Achaogen in a report on Monday, April 30th. Leerink Swann reissued an “outperform” rating on shares of Achaogen in a report on Sunday, March 4th. William Blair reissued an “outperform” rating on shares of Achaogen in a report on Wednesday, February 28th. SunTrust Banks cut their price objective on Achaogen to $16.00 and set a “buy” rating for the company in a report on Friday. Finally, ValuEngine raised Achaogen from a “sell” rating to a “hold” rating in a report on Monday, April 2nd. One analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $22.67.

In other news, major shareholder Robert W. Duggan bought 10,000 shares of the business’s stock in a transaction on Wednesday, February 14th. The stock was acquired at an average price of $10.96 per share, with a total value of $109,600.00. Following the completion of the purchase, the insider now directly owns 5,668,310 shares in the company, valued at $62,124,677.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Kenneth J. Hillan sold 4,606 shares of the company’s stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $10.67, for a total value of $49,146.02. The disclosure for this sale can be found here. In the last ninety days, insiders acquired 2,555,730 shares of company stock valued at $29,790,300 and sold 10,089 shares valued at $110,576. 7.80% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the business. MetLife Investment Advisors LLC bought a new stake in Achaogen in the fourth quarter valued at approximately $151,000. Clear Harbor Asset Management LLC bought a new stake in Achaogen in the fourth quarter valued at approximately $177,000. Ellington Management Group LLC bought a new stake in Achaogen in the fourth quarter valued at approximately $177,000. Tower Research Capital LLC TRC lifted its position in Achaogen by 375.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 18,648 shares of the biopharmaceutical company’s stock valued at $201,000 after purchasing an additional 14,725 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale bought a new stake in Achaogen in the first quarter valued at approximately $207,000. 76.72% of the stock is owned by institutional investors and hedge funds.

Shares of NASDAQ AKAO traded up $0.44 during midday trading on Thursday, hitting $12.85. 890,025 shares of the company’s stock were exchanged, compared to its average volume of 1,331,687. Achaogen has a 12-month low of $9.83 and a 12-month high of $27.49. The company has a current ratio of 4.83, a quick ratio of 4.83 and a debt-to-equity ratio of 0.08. The firm has a market capitalization of $524.51 million, a price-to-earnings ratio of -4.05 and a beta of 1.02.

Achaogen Company Profile

Achaogen, Inc, a late-stage biopharmaceutical company, focusses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae.

Get a free copy of the Zacks research report on Achaogen (AKAO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Achaogen (NASDAQ:AKAO)

Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply